Amantadine ER Curbs Levodopa-Induced Dyskinesia in PDAmantadine ER Curbs Levodopa-Induced Dyskinesia in PD
An investigational extended-release formulation of amantadine with a unique chronotherapeutic pharmacokinetic profile eases levodopa-induced dyskinesia in a phase 2/3 study. Medscape Medical News
CONCLUSIONS: There is only evidence of very low quality from a few small and poorly reported trials on the effect of benzodiazepines as an adjunctive treatment for antipsychotic-induced TD. These inconclusive results mean routine clinical use is not indicated and these treatments remain experimental. New and better trials are indicated in this under-researched area; however, as benzodiazepines are addictive, we feel that other techniques or medications should be adequately evaluated before benzodiazepines are chosen. PMID: 29352477 [PubMed - as supplied by publisher]
Authors: Citrome LL Abstract Many treatment interventions for tardive dyskinesia have been studied, but some have better evidence than others. Read this CME activity to get an expert's perspectives on the evidence for older and newer treatments so that you can minimize abnormal movements in your patients. PMID: 29345877 [PubMed - in process]
Authors: Kane JM Abstract Do you regularly screen for tardive dyskinesia in at-risk patients? Explore this CME activity by a well-known expert for information on rating scales for screening, available diagnostic criteria, assessment tips, and monitoring recommendations. PMID: 29345876 [PubMed - in process]
Authors: Correll CU Abstract What risk factors suggest that patients are more likely to develop tardive dyskinesia (TD)? Can TD symptoms be prevented? Read this CME activity to learn about the prevalence, epidemiology, and prevention of these abnormal movements from an expert. PMID: 29345874 [PubMed - in process]
Authors: Cummings MA, Proctor GJ, Stahl SM Abstract Tardive dyskinesia remains a significant, potentially stigmatizing or crippling adverse effect for any patient treated with an antipsychotic medication. While second- and third-generation antipsychotics have exhibited lower annual incidence rates for tardive dyskinesia than classic or first-generation agents, 3.9% versus 5.5%, the estimated incidence rate is only modestly lower. When coupled with the fact that second- and third-generation antipsychotic medications have come to be employed in treating a wider range of disorders (e.g., autism spectrum disorders, moo...
CONCLUSIONS: Based on currently available evidence, no confident statement can be made about the effectiveness of anticholinergics to treat people with antipsychotic-induced tardive dyskinesia. The same applies for the withdrawal of such medications. Whether the withdrawal of anticholinergics may benefit people with antipsychotic-induced TD should be evaluated in a parallel-group, placebo-controlled randomised trial, with adequate sample size and at least 6 weeks of follow-up. PMID: 29341071 [PubMed - as supplied by publisher]
CONCLUSIONS: Small trials of limited quality suggest that vitamin E may protect against deterioration of TD. There is no evidence that vitamin E improves symptoms of this problematic and disfiguring condition once established. New and better trials are indicated in this under-researched area, and, of the many adjunctive treatments that have been given for TD, vitamin E would be a good choice for further evaluation. PMID: 29341067 [PubMed - as supplied by publisher]
We describe a novel electrophysiologic signal from the motor cortex of patients with generalized dystonia - a discrete gamma-band oscillation induced by movement and associated with emergence of dystonia. This was observed using both invasive and non-invasive methods. This phenomenon is similar to the gamma oscillation reported in parkinsonian dyskinesia.
Abstract INTRODUCTION: Valbenazine is a selective VMAT2 inhibitor that the FDA approved in April 2017 for the specific treatment of tardive dyskinesia (TD), a movement disorder commonly caused by dopamine blocking agents. Valbenazine acts to decrease dopamine release, reducing excessive movement found in TD. Areas covered: This drug profile reviews the development of valbenazine and the clinical trials that led to its approval as the first treatment specific to TD. The literature search was performed with the PubMed online database. Expert Commentary: Two clinical trials assessing the efficacy of valbenazine have ...
Authors: Régis J, Carron R, Witjas T Abstract Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is the reference technique in Parkinson's disease (PD) at different stages of complications. Some patients cannot afford DBS due to anticoagulation or comorbidities or due to pecuniary reasons. Radiosurgery is a minimally invasive stereotactic technique, with no craniotomy and subsequently no risk of bleeding or infection. Its good safety efficacy profile has been established in the treatment of tremor, and the postoperative care issues are simple with a much shorter hospital stay (mean 48 h). The appl...